



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/033,777	01/03/2002	Jurgen Romisch	06478.1462	8563

7590 03/09/2004

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, DC 20005-3315

EXAMINER

MELLER, MICHAEL V

ART UNIT	PAPER NUMBER
----------	--------------

1654

DATE MAILED: 03/09/2004

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
P.O. Box 1450
ALEXANDRIA, VA 22313-1450
www.uspto.gov

MAILED
MAR 9 2004
GROUP

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**

Paper No. 2

Application Number: 10/033,777
Filing Date: January 03, 2002
Appellant(s): ROMISCH ET AL.

Sanya Sukduang
For Appellant

EXAMINER'S ANSWER

Art Unit: 1654

This is in response to the appeal brief filed 12/18/2003.

(1) *Real Party in Interest*

A statement identifying the real party in interest is contained in the brief.

(2) *Related Appeals and Interferences*

A statement identifying the related appeals and interferences which will directly affect or be directly affected by or have a bearing on the decision in the pending appeal is contained in the brief.

(3) *Status of Claims*

The statement of the status of the claims contained in the brief is incorrect. A correct statement of the status of the claims is as follows:

This appeal involves claims 1, 3, 5-21.

Art Unit: 1654

Claims 2, 4, 22-24 were withdrawn from consideration as not directed to the elected invention.

Applicant elected tranexamic acid and nonionic detergent as their elected species as noted in their response dated 4/10/2003.

(4) Status of Amendments After Final

The appellant's statement of the status of amendments after final rejection contained in the brief is correct.

(5) Summary of Invention

The summary of invention contained in the brief is correct.

(6) Issues

The appellant's statement of the issues in the brief is correct.

(7) Grouping of Claims

Appellant's brief includes a statement that claims 1, 3, 5-21 stand or fall together but do not provide reasons as set forth in 37 CFR 1.192(c)(7) and (c)(8). They stand or fall together since one 35 USC 103 rejection was made over all the claims.

(8) Claims Appealed

The copy of the appealed claims contained in the Appendix to the brief is correct.

Art Unit: 1654

(9) Prior Art of Record

4,465,662	Sato et al.	8-1984
5,589,363	Roy et al.	12-1996
5,604,202	Kessler et al.	2-1997
JP 02000023696	Roemisch et al.	1/2000
EP 0952215	Romisch et al.	10-1999

(10) Grounds of Rejection

The following ground(s) of rejection are applicable to the appealed claims:

Claims 1,3, 5-21 are rejected under 35 U.S.C. 103(a) as being unpatentable over JP 2000-023696 (abstract) or EP 952215 (abstract, page 2) taken with Sato et al. (abstract, col. 1, lines 16-25, col. 3, lines 5-25, example 4) and further in view of Roy et al. (col. 34, line 55-col. 35, line 15) or Kessler et al. (col. 3, line 55-col. 4, line 11).

JP and EP teach that a protease which activates blood coagulation factor VII can be stabilized using sodium citrate, see page 2, bottom of EP.

Sato teaches that tranexamic acid is stabilized using CMC and carragennnan (example 4) and also shows using a protease with it (col. 3, lines 6-23).

Art Unit: 1654

Roy and Kessler teach that the other ingredients to be added to the composition, detergents, sugar, amino acid are known in the art to stabilize compositions such as the claimed invention.

Thus, since the components are used individually in the art for the same purpose to stabilize a composition, then it would have been obvious to use them together to produce a stabilized composition.

(11) *Response to Argument*

Appellant first argues that JP and EP do not teach all of the claimed elements. This is a rejection with a combination of references rejected under 35 USC 103.

Appellant then states that Roy, Kessler and Sato do not make up for the deficiencies by showing how what they have to teach relates to the claimed enzyme. The rejection was made under 35 USC 103. It was made with a combination of references that show that the individual ingredients of the composition can be used individually in the art for the same purpose, namely to stabilize a composition.

Appellant next argues that Sato in fact teaches away from stabilizing because according to appellant Sato teaches that tranexamic acid does not stabilize. Upon further inspection of Sato it is clear that appellant took this statement from a part of the patent which was discussing the background problems in the art and upon further inspection of the Sato patent it is clear that Sato found the tranexamic acid to stabilize compositions, see example 4.

Art Unit: 1654

For the above reasons, it is believed that the rejections should be sustained.

Respectfully submitted,




Michael V. Meller
Primary Examiner
Art Unit 1654

MVM
March 4, 2004


Conferees:

Brenda Brumback
Andrew Wang

Finnegan, Henderson, Farabow,
Garrett & Dunner, L.L.P.
1300 I Street, N.W.
Washington, DC 20005-3315



BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600
Conferee



ANDREW WANG
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600